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Diﬀerent approaches have been applied to develop highly attenuated rabies virus vaccines for oral vaccination of mesocarnivores.
One prototype vaccine construct is SAD dIND1, which contains a deletion in the P-gene severely limiting the inhibition of type-1
interferon induction. Immunogenicity studies in foxes and skunks were undertaken to investigate whether this highly attenuated
vaccine would be more immunogenic than the parental SAD B19 vaccine strain. In foxes, it was demonstrated that SAD dIND1
protected the animals against a rabies infection after a single oral dose, although virus neutralizing antibody titres were lower than
in foxes orally vaccinated with the SAD B19 virus as observed in previous experiments. In contrast, skunks receiving 107.5 FFU
SAD dIND1 did not develop virus neutralizing antibodies and were not protected against a subsequent rabies infection.
1.Introduction
The European rabies landscape has changed notably in
the last 30 years as a result of oral vaccination of foxes
(Vulpes vulpes) against rabies. Many countries in West
and Central Europe eliminated terrestrial wildlife rabies by
distributing oral rabies vaccine (ORV) baits. The red fox is
no longer the sole target species for those baits; oral rabies
vaccination programmes are targeted at many diﬀerent
animal species in many diﬀerent regions, worldwide. The
presently available commercial ORV are all replication-
competent viruses and therefore pose an intrinsic safety risk.
Vaccine virus-associated rabies cases have been reported in
target and nontarget species [1–3]. Also, adverse reactions
have been observed in humans after direct exposure to
a recombinant ORV [4, 5]. Furthermore, several animal
species are diﬃcult to vaccinate against rabies by the oral
route using the available products. Hence, an ongoing
programme for safer ORV candidates with improved eﬃcacy
has been initiated since the ﬁrst ORVs became commercially
available [6]. One group of candidates is based on site-
directed mutations of the rabies virus genome. Originally,
these eﬀorts focused on the gene encoding the rabies virus
glycoprotein. The principal modality of protection against
rabies virus is the generation of virus-neutralising antibodies
(VNA) against the glycoprotein [6]. However, other facets
of innate and adaptive immunity also contribute to virus
clearance. Moreover, the role of cell-mediated and humoral2 Advances in Preventive Medicine
immunity against the nucleoprotein, matrix protein, and
phosphoprotein in the protection of animals against rabies
remains unclear. For these reasons, other rabies virus genes
oﬀer possibilities for the development of highly attenuated
viruses, for example, the ability of the phosphoprotein to
counteract transcriptional activation of interferon (IFN)
Type 1 by interfering with the phosphorylation of IRF-3
[7, 8]. A site-directed deletion of a small internal domain
(aa 176–186) of the phosphoprotein abolishes the ability to
eﬃciently prevent IRF-3 activation and thereby preventing
IFN Type 1 induction [9]. A virus construct, SAD dIND1,
was developed comprising the aa 176–181 deletion in the
phosphoprotein that had lost most of its inhibitory activity
in preventing IRF-3 activation. This construct was shown to
becompletelyavirulentinadultmiceafteri.c.administration
[9], underscoring the type I IFN system as probably the
most powerful antiviral response capable of controlling viral
infections in the absence of adaptive immunity [10]. A pilot
experiment in two wildlife reservoir species was initiated
to investigate whether SAD dIND1 is more immunogenic
than the parental strain SAD B19. The two wildlife reservoir
species assessed included the highly susceptible red fox and
the striped skunk (Mephitis mephitis); the latter is an animal
species notoriously refractory to oral rabies vaccination [11,
12]. Although foxes vaccinated with SAD dIND1 by the oral
route survived a subsequent rabies challenge, the construct
was not able to protect skunks against a subsequent rabies
infection.
2.MaterialandMethods
2.1. Virus Construct. The SAD dIND1 construct was devel-
oped as previously described [9] using the recombinant
rabies virus SAD L16 comprising the consensus sequence of
the ORV strain SAD B19. Through site-directed mutagenesis
codons specifying the amino acids 176 to 181 of the phos-
phoprotein were deleted. The virus material used in these
studies was propagated using a MOI of 0.1 in BSR T7/5 cells,
a BHK-derived cell line stably expressing t7 RNA polymerase
[13].SADdIND1isconsideredageneticallymodiﬁedorgan-
ism (GMO) and is classiﬁed as a BSL2 pathogen in Germany.
The permits for the animal studies with such GMOs have
been obtained from the appropriate regulatory authorities
(AZ-66230-1501-3, Landesverwaltungsamt Sachsen-Anhalt,
Germany).
2.2. Challenge Virus. The challenge virus, CVS/USA/TX
Coyote/295/R/061893, was obtained from CDC (USA) and
originally isolated from a salivary gland of a coyote (Canis
latrans). The original challenge virus had been inoculated
in a fox and reisolated from the brain after the animal
succumbed to rabies. The virus isolate was passaged once in
a fox and ﬁnally reisolated from the salivary gland. The foxes
and skunks were administered 1.0mL of the challenge virus
(105.1 MICLD50) in the M. masseter by the i.m. route.
2.3. Animals. The captive bred animals were obtained from
diﬀerent commercial sources; foxes from Fa. Phu Foxpol,
Poland, and skunks from AGHIA Birds Company, the
Table 1: Summary of the experimental design with SAD dIND1 in
foxes and skunks (o.g.: oral gavage; i.m: intramuscularly).
Animal Number Dose
FFU/mL Route Observation
period (days)
Fox 3 106.3 o.g. 62
Fox 3 107.3 o.g. 62
Fox 2 106.3 i.m. 62
Skunk 3 107.5 o.g. 45
Netherlands. The animals were identiﬁed by implantation of
a microchip (UNO BV, Zevenaar, The Netherlands). Vacci-
nated foxes were kept individually in cages housed within an
isolation unit of the animal house at IDT. Vaccinated skunks
were caged in groups within an isolation unit until the time
of challenge when each animal was housed individually. The
control animals were housed in the outside animal enclosure
until administration of the challenge virus when the animals
were also transferred to individual cages within an isolation
room. Foxes were fed once a day and water was oﬀered
ad libitum. Foxes received fresh commercial food for fur
animals, (Schirmer & Partner, Doehlen [D]). The skunks
were fed commercial dry pet food twice a day (100g =
25g cat food (Drei-Mix, Miehlitz KG) + 75g dog food
(Good deal, Voro-Dog Vertrieb, Enger), soaked with water
substituted with 5g vitamin mixture per animal once per
day (Multivit, Inropharm GmbH F¨ urstenzell)). The skunks
were also fed fresh fruit daily. The animals were observed at
least once a day. After challenge, the animals were observed
more frequently, and, on onset of CNS-related clinical signs,
the animals were euthanized with T61 intracardial, 0.3mL
per body weight kilogram (Intervet Deutschland GmbH,
Unterschleissheim [D]), after sedation with a ketamine 1.0–
2.0mL 10% (WDT eG, Garbsen [D])-xylazine [Xylariem,
Riemser Arzneimittel, Riems [D]) mixture.
The housing conditions of the animals met the condi-
tions as stated in the German animal welfare act §2&2a
and the recommendations of the GV-SOLAS (Society for
laboratoryanimal science).Allexperiments wereundertaken
in accordance with the German animal welfare act §8a, Abs.
1a n d2 . f .
2.4. Vaccination. Eight adult foxes were vaccinated with
1.5mL SAD dIND1 using diﬀerent doses and routes of
administration (Table 1) .T h ea n i m a l sw e r ec h a l l e n g e d
together with 2 control animals 62 days after administration
of SAD dIND1. Fifty days after challenge, all surviving
animals were euthanized. Blood samples were taken on day
0 (prior to vaccination), 28, 58, and 112 after vaccina-
tion. During a dose-dependent study with diﬀerent vaccine
candidates, 3 skunks received 107.5 FFU SAD dIND1 by
direct oral instillation and were challenged 45 days later
together with 2 control animals. Blood samples of the skunks
were collected—5, 28, 42, and 57 days after vaccination. All
animals were sedated during administration of SAD dIND1
and blood sampling.Advances in Preventive Medicine 3
2.5. Assays
2.5.1. FAT/IHC. The presence of rabies virus antigen in fox
brain samples was examined using the Fluorescent Antibody
Test (FAT) as described by Dean et al. [14]. Samples of hip-
pocampus fromskunks wereﬁxed in 4% phosphate-buﬀered
formaldehyde and processed for paraﬃn-wax embedding
and immunohistochemistry (IHC), slightly modifying a
method described previously [15]. The hippocampus of
skunks has been shown to be highly suitable for these
purposes [16].
2.5.2. RFFIT. Blood samples collected were examined for
the presence of rabies VNA using the rapid ﬂuorescent
focus inhibition test (RFFIT) [17], with the modiﬁcations
of that method as described by Cox and Schneider [18].
Prior to testing, serum samples were heat-inactivated for
30 minutes at 56◦C. To calculate the titer, a 50% reduction
in concentration of rabies virus in vitro was calculated by
use of inverse interpolation (SAS software 9.2). The rabies
VNA titers were converted to international units (IU) by
comparison with international standard immunoglobulin
adjusted to 0.5U/mL, which served as a positive control.
3. Results
All foxes vaccinated with SAD dIND1 survived the lethal
challenge irrespective of dose and route of administration
and were euthanized 50 days after challenge. Meanwhile,
both control animals were euthanized upon showing clinical
signstorabiesinfection10and11daysafterchallenge.Rabies
antigen was detected in brain material of both animals. All
foxes receiving SAD dIND1 seroconverted with VNA titres
greater than the arbitrary threshold of 0.5IU/mL (Table 2).
The level of rabies VNA antibodies indicated a dose-and
route-dependent response. In contrast to the foxes, SAD
dIND1 did not confer suﬃcient immunity in skunks to
prevent infection after challenge exposure. Unfortunately,
the small sample size of skunks was even further reduced.
One skunk receiving SAD dIND1 was excluded from chal-
lenge because it developed a severe dermatitis during the
observationperiodandwaslocatedtoanotherisolationunit.
All 4 remaining animals succumbed to rabies as conﬁrmed
by IHC. The two control animals and the two vaccinated
animals were euthanized upon showing clinical signs of CNS
disorders on day 13 after challenge. None of the skunks
that received SAD dIND1 developed detectable levels of
rabies VNA during the observation period (Table 3). After
challenge,bothcontrolanimalshaddetectablelevelsofVNA,
meanwhile both animals that received SAD dIND1 remained
seronegative.
4. Discussion
One of the major concerns with the distribution of ORVs
for wildlife in the environment is the risk that nontarget
species, including humans, will contactthese vaccine viruses.
The safety concerns associated with the ﬁrst generation
Table 2: The titre of virus neutralizing antibodies measured in the
foxbloodsamplesbyRFFITareexpressedinIU/mL.Theﬁnalblood
sample (B3) was taken 50 days after challenge (GMT; geometric
mean titre; o.g: oral gavage; i.m: intramuscularly).
Animal Route
Dose
FFU/mL
(10 log)
B1
(day 28)
B2
(day 58)
B3
(day 112)
7879 o.g. 7.3 47.5 23.8 80.0
0200 o.g. 7.3 11.9 47.5 80.0
9787 o.g. 7.3 56.6 11.9 47.5
GMT 31.7 23.8 67.2
6170 o.g. 6.3 14.2 14.2 40.0
7287 o.g. 6.3 11.9 11.9 80.0
9788 o.g. 6.3 14.2 10.0 20.0
GMT 13.4 11.9 40.0
3568 i.m. 6.3 23.8 23.8 56.6
6061 i.m. 6.3 28.3 23.8 91.9
GMT 26.0 23.8 72.1
Table 3: The results of the blood samples from the skunks,
including the control animals; the titre of the virus neutralizing
antibodies are expressed in IU/mL and determined by RFFIT (n.d:
not determined).
Animal Construct B0
(day 5)
B1
(day 28)
B2
(day 42)
B3
(day 57)
9892 SAD
dIND1 0.04 0.03 0.03 0.15
9893∗ SAD
dIND1 0.09 0.06 0.09 n.d.
9895 SAD
dIND1 0.11 0.06 0.06 0.11
9899 control 0.06 n.d n.d 3.44
9897 control 0.05 n.d n.d 4.31
∗Animal developed severe dermatitis and was excluded for challenge.
attenuatedORVledtothedevelopmentofdiﬀerentrecombi-
nant vaccine vectors expressing the rabies virus glycoprotein;
for example, vaccinia virus, human adenovirus type 5,
pseudorabies virus, canine herpesvirus, and canine aden-
ovirus type 2 constructs [19–24]. Some of these replication
competent vectors are based on human pathogens and
are therefore also not without risks, especially in view of
immunocompromised persons. Unfortunately, replication-
deﬁcient constructs like an E1-deleted human adenovirus
type-5 expressing the rabies virus glycoprotein did not
induce detectable rabies VNA after oral administration
[25]. The balance that must be attained is constructing a
viral delivery system that is fully attenuated to render it
safe and prevent replication and yet have suﬃcient viral
characteristics that allow uptake into permissive cells and
protein production to induce an immune response. A
further important limitation of some of these recombinant
constructs is the interference of preexisting immunity to
the vector virus, severely compromising its eﬃcacy [26–28].
Preexisting immunity to the vector virus would not be4 Advances in Preventive Medicine
important for highly attenuated rabies virus constructs.
Therefore, several rabies virus constructs have been selected
or developed and tested for their potential use as a rabies
vaccine, including constructs with site-directed deletions in
the phosphoprotein or its complete deletion [29–31]. For
example, removal of Dynein Light Chain 8 binding site motif
substantially reduced viral transcription and replication
in the central nervous system [32]. Another strategy was
to make the expression of the essential phosphoprotein
dependent on translation and not transcription [33]. The
SAD dIND1 construct uses a diﬀerent approach which is
aimed at inducing an improved innate immune response in
vaccinated animals. The deletion introduced by site-directed
mutagenesis interferes with the virus countermeasures to
inhibit induction of IFN [34]. The enhanced antiviral host
response was demonstrated in mice that were inoculated i.c.
with SAD dIND1 or with the parental strain SAD L16. While
all mice inoculated with SAD L16 succumbed to rabies,
all SAD dIND1 inoculated animals survived [9]. An oral
vaccine candidate must be safe and eﬃcacious, preferably
conferring life-long immunity, after the consumption of a
single bait [35]. Although all foxes vaccinated with SAD
dIND1 were fully protected against the severe rabies virus
challenge, the VNA was lower than observed in foxes oﬀered
a bait containing 106.3 FFU of the vaccine strain SAD B19
[36]. The geometric mean titre of 27 foxes was 43.5 and
33.9IU/mL 60 and 110 days after the animals had consumed
a SAD B19 vaccine bait, respectively. The diﬀerence in VNA
titre is more notable considering that the administration
of the SAD B19 vaccine was by bait consumption instead
of by direct oral gavage for SAD dIND1. The lower VNA
titres observed in the SAD dIND1 vaccinated animals could
have been a result of the IFN Type 1 induced shift towards
a Th1 immune response [7]. However, it is more probably
the reduced viral growth and antigenic presentation of the
rabies virus glycoprotein to antigen presenting cells. An
increased induction of IFN by SAD dIND-infected cells
would result in limited viral spread because noninfected
neighbouring cells have been placed into an “antiviral” state
by expression of antiviral IFN stimulated genes through
the IFN-signalling pathway [10]. Rabies virus released from
primary infected cells replicate ineﬃciently in such cells.
Unfortunately, SAD dIND1 failed to elicit detectable levels
of VNA in skunks, and consequently none of the animals
induced a protective immune response against the challenge.
The reduced ability of SAD dIND1 to induce rabies VNA
compared to the SAD B19 vaccine strain was also shown
in skunks. During a previous safety study with SAD B19,
3 of seven skunks receiving107.9 FFU by direct oral gavage
seroconverted, and all three animals had measurable levels
of rabies virus VNA (>5.0IU/mL) 296 days after vaccination
[37]. From this study, it can be concluded that the enhanced
IFNproductioninresponsetoSADdIND1resultsinastrong
antiviral eﬀect that outperforms the acknowledged immune-
stimulatory eﬀect of type I IFN. In order to make the
highly attenuated replication competent virus, SAD dIND,
an eﬀective rabies vaccine candidate for oral vaccination
of species including the striped skunk its immunogenicity
must be improved. This could be achieved by altering the
deleted domain, whereby the inhibitory eﬀect on IRF-3
activation can be adjusted. For example, another construct
(SAD dIND2) with a phosphoprotein lacking amino acids
182–186 instead of 176–181 (SAD dIND1) inhibits IRF-3
activation less eﬃciently [9]. Therefore, it can be assumed
that, in SAD dIND2 infected hosts, there is less IFN Type
1 induction subsequently leading to more pronounced viral
spread and antigenic presentation. However, SAD dIND2
was in contrast to SAD dIND1 not completely avirulent
in mice [9], once more underscoring the diﬃculties in
determining the delicate balance between safety and eﬃcacy.
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